Clinical trial NCT00672295 (phase 1, status: completed)
Conditions: ovarian cancer, peritoneal cancer, fallopian tube cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02, C57.00, C57.01, C57.02
Drugs: dasatinib, paclitaxel, and carboplatin
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Pts must have histologic or cytologic evidence of ovarian, peritoneal, or tubal cancer

          -  All pts must have measurable disease

          -  > 18 yrs

          -  Expected survival of at least 3 months

          -  Pts must have GOG performance status pf 0, 1 or 2

          -  Pts must have adequate:Bone marrow function, renal function, hepatic function,
             neurologic function

          -  No chemo, radiotherapy, biologic, hormonal, or investigational drug therapy within 28
             days prior to study entry

          -  Pts may have had up to 3 prior cytotoxic chemo regimens including prior treatment w
             carboplatin & paclitaxel

          -  Capable of providing written informed consent

          -  Pts of childbearing potential must have negative serum pregnancy test prior to study
             entry & be practicing effective method of birth control during course of study, in
             manner such that risk of failure is minimized. Prior to study enrollment, women of
             childbearing potential must be advised of importance of avoiding pregnancy during
             trial participation & potential risk factors for unintentional pregnancy

          -  Pts must have tissue block from their tumor available for evaluation for microarray &
             immunoblot analyses. Pretreatment tumor tissue may be obtained from either archival
             tissue or be obtained by guided by guided core needle or simple biopsy it must be
             performed within four weeks prior to enrollment on study. Pts must have tumor that is
             accessible to biopsy & consent to undergo post-treatment biopsy after cycle #2 of
             treatment as well

        Exclusion Criteria:

          -  Pts w epithelial ovarian tumors of low malignant potential (borderline tumor)

          -  Pts w history of other invasive malignancies, w exception of non-melanoma skin cancer,
             are excluded if there is any evidence of other malignancy being present within last 5
             yrs

          -  Pts who have following cardiac conditions: uncontrolled angina or myocardial
             infarction within past 6 months; diagnosed or suspected congenital long QT syndrome;
             Any history of clinically significant ventricular arrhythmias; Prolonged QTc interval
             on pre-entry electrocardiogram on both Fridericia & Bazett's correction; uncontrolled
             hypertension

          -  History of significant bleeding disorder unrelated to cancer, including: diagnosed
             congenital bleeding disorders; diagnosed acquired bleeding disorder within 1 yr

          -  Pts currently taking drugs that are generally accepted to have risk of causing
             Torsades de Pointes including: quinidine, procainamide, disopyramide; amiodarone,
             sotalol, ibutilide, dofetilide; erythromycins, clarithromycin; chlorpromazine,
             haloperidol, mesoridazine, thioridazine, pimozide; cisapride, bepridil, droperidol,
             methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine,
             sparfloxacin, lidoflazine

          -  Serum creatinine > 1.5 times institutional upper limits of normal

          -  Pts taking certain concomitant medications, consider following prohibitions:
             medications that inhibit platelet function or anticoagulants

          -  Pts who have received radiation therapy to > 30 percent of bone marrow

          -  Pts w history of grade 3 hypersensitivity to paclitaxel or carboplatin

          -  Pts w septicemia, severe infection, acute hepatitis, other uncontrolled severe medical
             conditions